2021
Yale Cancer Center Precision Medicine Tumor Board: molecular findings alter a diagnosis and treatment plan
Gibson JA, Finberg KE, Nalbantoglu I, Cecchini M, Ganzak A, Walther Z, Sklar JL, Eder JP, Goldberg SB. Yale Cancer Center Precision Medicine Tumor Board: molecular findings alter a diagnosis and treatment plan. The Lancet Oncology 2021, 22: 306-307. PMID: 33662283, DOI: 10.1016/s1470-2045(20)30683-5.Peer-Reviewed Original Research
2018
Optimal Intraoperative Assessment of Gastric Margins
Celli R, Barbieri AL, Colunga M, Sinard J, Gibson JA. Optimal Intraoperative Assessment of Gastric Margins. American Journal Of Clinical Pathology 2018, 150: 353-363. PMID: 30020407, DOI: 10.1093/ajcp/aqy062.Peer-Reviewed Original ResearchConceptsIntraoperative pathology consultationGastric marginPositive marginsTumor distanceMajority of casesRepresentative sectionsR0 resectionConsecutive patientsGastroesophageal junctionTumor sizeNegative marginsPatient outcomesIntraoperative assessmentPathology consultationPatientsStrong associationMargin assessment
2017
Clinicopathologic and outcome study of sessile serrated adenomas/polyps with serrated versus intestinal dysplasia
Cenaj O, Gibson J, Odze RD. Clinicopathologic and outcome study of sessile serrated adenomas/polyps with serrated versus intestinal dysplasia. Modern Pathology 2017, 31: 633-642. PMID: 29271414, DOI: 10.1038/modpathol.2017.169.Peer-Reviewed Original ResearchConceptsSessile serrated adenomas/polypsSerrated adenomas/polypsAdenomas/polypsIntestinal dysplasiaConventional adenomasSerrated dysplasiaPrevalence of adenocarcinomaType of dysplasiaHigh-grade lesionsDysplasia-carcinoma sequenceLow-grade dysplasiaNeoplastic precursor lesionsHigh rateDysplasia subtypeControl patientsPathologic featuresMean ageMicrosatellite unstable cancersBiologic featuresInvasive carcinomaPrecursor lesionsNeoplastic lesionsPrevalence ratesOutcome studiesPatients
2015
Gastric Fundic Gland Adenocarcinoma With Chief Cell Differentiation
Parikh ND, Gibson J, Aslanian H. Gastric Fundic Gland Adenocarcinoma With Chief Cell Differentiation. Clinical Gastroenterology And Hepatology 2015, 13: a17-a18. PMID: 26215839, PMCID: PMC4829391, DOI: 10.1016/j.cgh.2015.07.023.Peer-Reviewed Original ResearchClinical, pathologic, and outcome study of hyperplastic and sessile serrated polyps in inflammatory bowel disease
Shen J, Gibson JA, Schulte S, Khurana H, Farraye FA, Levine J, Burakoff R, Cerda S, Qazi T, Hamilton M, Srivastava A, Odze RD. Clinical, pathologic, and outcome study of hyperplastic and sessile serrated polyps in inflammatory bowel disease. Human Pathology 2015, 46: 1548-1556. PMID: 26297256, DOI: 10.1016/j.humpath.2015.06.019.Peer-Reviewed Original ResearchConceptsInflammatory bowel diseaseNeoplastic lesionsHyperplastic polypsFlat dysplasiaIBD patientsBowel diseaseAdenoma-like dysplasiaTraditional serrated adenomasSessile serrated polypsAverage followSurgical resectionClinicopathological featuresColon resectionSporadic adenomasSerrated polypsLower riskSerrated pathwayPatientsSerrated adenomasLesionsDysplasiaAdenoma/AdenocarcinomaResectionAdenomas